Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Marielle Gallegos Ruiz"'
Autor:
Vincent A. Miller, Pasi A. Jänne, David M. Jackman, Marielle Gallegos Ruiz, Gregory J. Riely, Beow Y. Yeap, Bruce E. Johnson, Lecia V. Sequist, Giuseppe Giaccone, Leigh-Anne Cioffredi
Publikováno v:
Clinical Cancer Research. 15:5267-5273
Purpose: The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines patient data from five trials in predominantly Western populations to asses
Autor:
Elisa Giovannetti, Filippo Cortesi, Godefridus J. Peters, Mario Del Tacca, Romano Danesi, Valentina Mey, Sara Nannizzi, Francesco Crea, Marielle Gallegos Ruiz, S. Ricciardi
Publikováno v:
Molecular Cancer Therapeutics, 8(7), 1964-1973. American Association for Cancer Research Inc.
Crea, F, Giovannetti, E, Cortesi, F, Mey, V, Nannizzi, S, Ruiz, M, Ricciardi, S, Del Tacca, M, Peters, G J & Danesi, R 2009, ' Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines ', Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 1964-1973 . https://doi.org/10.1158/1535-7163.MCT-09-0027
Crea, F, Giovannetti, E, Cortesi, F, Mey, V, Nannizzi, S, Ruiz, M, Ricciardi, S, Del Tacca, M, Peters, G J & Danesi, R 2009, ' Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines ', Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 1964-1973 . https://doi.org/10.1158/1535-7163.MCT-09-0027
Irinotecan is a topoisomerase-I (Top-I) inhibitor used for the treatment of colorectal cancer. DNA demethylating agents, including 5-azacytidine (5-aza), display synergistic antitumor activity with several chemotherapy drugs. 5-Aza may enhance irinot
Autor:
Jose A. Rodriguez, Katrien Grünberg, Frank Rijmen, Marielle Gallegos Ruiz, Karijn Floor, Giuseppe Giaccone
Publikováno v:
Scopus-Elsevier
Cellular Oncology, Vol 29, Iss 3, Pp 257-264 (2007)
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
Cellular Oncology, Vol 29, Iss 3, Pp 257-264 (2007)
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
Background: Mutational analysis of the Epidermal Growth Factor Receptor (EGFR) and K-ras genes to select non-small cell lung cancer (NSCLC) patients for treatment with novel EGFR tyrosine kinase inhibitors is an appealing possibility currently under
Autor:
Godefridus J, Peters, Abolfazl, Avan, Marielle Gallegos, Ruiz, Vanessa, Orsini, Amir, Avan, Elisa, Giovannetti, Egbert F, Smit
Publikováno v:
Anticancer research. 34(1)
Platinum combinations are the mainstay of treatment for non-small cell lung cancer (NSCLC), while for pancreatic cancer platinum combinations are being given to good-performance status patients. These platinum combinations consist of cis- or carbopla
Autor:
Tanja D. de Gruijl, Hester van Cruijsen, Giuseppe Giaccone, Marielle Gallegos Ruiz, Paul van der Valk
Publikováno v:
van Cruijsen, H, Ruiz, M, van der Valk, P, de Gruijl, T D & Giaccone, G 2009, ' Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer ', BMC Cancer, vol. 9 . https://doi.org/10.1186/1471-2407-9-180
BMC Cancer, Vol 9, Iss 1, p 180 (2009)
BMC Cancer
BMC Cancer, 9. BioMed Central
BMC Cancer, Vol 9, Iss 1, p 180 (2009)
BMC Cancer
BMC Cancer, 9. BioMed Central
Background Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87f8b9cfc4080e35281802fcdbffd3e4
https://research.vumc.nl/en/publications/3adddd67-5b06-4cf8-9f3b-1c3a923151f4
https://research.vumc.nl/en/publications/3adddd67-5b06-4cf8-9f3b-1c3a923151f4
Autor:
I. Garassino, Jose A. Rodriguez, Giovanni Luca Ceresoli, Giuseppe Giaccone, Armando Santoro, Paolo Andrea Zucali, Paolo M. Comoglio, Elisa Giovannetti, Massimo Roncalli, Karijn Floor, Annarita Destro, Marielle Gallegos Ruiz, Marileila Varella-Garcia
Publikováno v:
Ann Oncol
Annals of Oncology, 19(9), 1605-1612. Oxford University Press
Zucali, P A, Ruiz, M G, Giovannetti, E, Destro, A, Varella-Garcia, M, Floor, K, Ceresoli, G L, Rodriguez, J A, Garassino, I, Comoglio, P, Roncalli, M, Santoro, A & Giaccone, G 2008, ' Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors ', Annals of Oncology, vol. 19, no. 9, pp. 1605-1612 . https://doi.org/10.1093/annonc/mdn240
Annals of Oncology, 19(9), 1605-1612. Oxford University Press
Zucali, P A, Ruiz, M G, Giovannetti, E, Destro, A, Varella-Garcia, M, Floor, K, Ceresoli, G L, Rodriguez, J A, Garassino, I, Comoglio, P, Roncalli, M, Santoro, A & Giaccone, G 2008, ' Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors ', Annals of Oncology, vol. 19, no. 9, pp. 1605-1612 . https://doi.org/10.1093/annonc/mdn240
Background: Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4970f6bb5f4cef2f3972f8facf3929
https://europepmc.org/articles/PMC7360138/
https://europepmc.org/articles/PMC7360138/
Autor:
Egbert F. Smit, Bauke Ylstra, Jose A. Rodriguez, Karijn Floor, Paul Roepman, Ewa Jassem, Thomas Muley, Gerrit A. Meijer, Len Neckers, Kristin Beebe, Jacek Niklinski, Marielle Gallegos Ruiz, Nico van Zandwijk, Wolter J. Mooi, Giuseppe Giaccone
Publikováno v:
PLoS ONE, 3(3). Public Library of Science
PLoS ONE, Vol 3, Iss 3, p e0001722 (2008)
PLoS ONE
Gallegos-Ruiz, M I, Floor, K, Roepman, P, Rodriguez, J A, Meijer, G A, Mooi, W J, Jassem, E, Niklinski, J, Muley, T, van Zandwijk, N, Smit, E F, Beebe, K, Neckers, L, Ylstra, B & Giaccone, G 2008, ' Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target ', PLoS ONE, vol. 3, no. 3, pp. e0001722 . https://doi.org/10.1371/journal.pone.0001722
PLoS ONE, Vol 3, Iss 3, p e0001722 (2008)
PLoS ONE
Gallegos-Ruiz, M I, Floor, K, Roepman, P, Rodriguez, J A, Meijer, G A, Mooi, W J, Jassem, E, Niklinski, J, Muley, T, van Zandwijk, N, Smit, E F, Beebe, K, Neckers, L, Ylstra, B & Giaccone, G 2008, ' Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target ', PLoS ONE, vol. 3, no. 3, pp. e0001722 . https://doi.org/10.1371/journal.pone.0001722
BackgroundLung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer (NSCLC) represents 85% of all lung cancers. Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f144dfd4071fa3551ba0ede8837cdf79
https://research.vumc.nl/en/publications/626a6e57-d5d4-44f1-8afd-0d7c82f66237
https://research.vumc.nl/en/publications/626a6e57-d5d4-44f1-8afd-0d7c82f66237
Autor:
Thierry Le Chevalier, Dalila Oulid-Aissa, Giuseppe Giaccone, Jean-Charles Soria, Nick Thatcher, Pasi A. Jänne, Marielle Gallegos Ruiz, Jose A. Rodriguez, Egbert F. Smit
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(20 Pt 1)
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome. Experimental Design:
Publikováno v:
Journal of Thoracic Oncology. 2:S395-S396
Publikováno v:
Scopus-Elsevier
Erlotinib, a potent inhibitor of the tyrosine-kinase (TK) activity of human epidermal growth factor receptor (HER1/EGFR), produces significant survival and quality of life benefits in patients with previously treated advanced-stage non-small-cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::924442b0cba7154ba25dec1f1b4e3a78
http://www.scopus.com/inward/record.url?eid=2-s2.0-33845398258&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-33845398258&partnerID=MN8TOARS